Subscribe to news

Shareholder Structure

Today, share capital of Human Stem Cells Institute (HSCI) amounts to RUB 7,500,000 and consists of 75,000,000 ordinary (voting) shares, each with a par value of RUB 0.1.

Ownership structure as of May 29, 2017 
(the record date for AGM on June 21, 2017)


* Change in HSCI's shareholding structure as of December 27, 2013 - see: Press-release (January 14,2014)

** Treasury shares of HSCI, which occurred due to the mandatory buy-back in 2011 (4.67% of HSCI’s share capital), were realized during the year 2012 as required by law, with the part of them (in the amount of 4.01% of HSCI’s share capital) having been brought to the charter capital of HSCI’s 100% subsidiary NextGen LLC as an additional contribution.

NextGen LLC (Russia) focuses on R&D and marketing of products for gene therapy, the development of treatments using gene-therapy drugs and the method of therapeutic angiogenesis. In addition, the Company works on the development of new ways to prevent/treat inherited diseases and genetic disorders. IP owner, Skolkovo resident.

The Company’s largest shareholders as of May 29, 2017 (>5%)

% of share capital % of ordinary shares
(voting shares)
Artur Isaev, CEO HSCI, PJSC 16.83 16.83
Maria Isaeva 32.53 32.53
Dynamic Solutions Ldt. (Seychelles) 24.00 24.00

On the record date of May 29, 2017, the number of the Company’s shareholders amounted to 1,046.

As of May 29, 2017, HSCI’s free float was approximately 20% of the total share capital.